Filtered By:
Source: Acta Pharmacologica Sinica

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 122 results found since Jan 2013.

WIN55,212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats.
Conclusion:Tau-1 is expressed in NG2(+) cells following permanent focal cerebral ischemic injury. Treatment with WIN55,212-2 reduces the number of tau-1(+)/NG2(+) cells and promotes NG2(+) cell proliferation in the stroke penumbra, which are mediated partially via CB1 and may contribute to its neuroprotective effects. PMID: 23202804 [PubMed - in process]
Source: Acta Pharmacologica Sinica - January 1, 2013 Category: Drugs & Pharmacology Authors: Sun J, Fang YQ, Ren H, Chen T, Guo JJ, Yan J, Song S, Zhang LY, Liao H Tags: Acta Pharmacol Sin Source Type: research

Humanized cerebral organoids-based ischemic stroke model for discovering of potential anti-stroke agents
In this study we compared the cell composition of COs at different culture time and explored the cell types, cell ratios and volume size of COs at 85 days (85 d-CO). The 85 d-CO with diameter more than 2 mm was chosen for establishing humanized ischemic stroke model of OGD. By determining the time-injury relationship of the model, we observed aggravated ischemic injury of COs with OGD exposure time, obtaining first-hand evidence for the damage degree of COs under different OGD condition. The sensitivity of the model to ischemic injury and related treatment was validated by the proven pan-Caspase inhibitor Z-VAD-FMK (20 μM...
Source: Acta Pharmacologica Sinica - September 13, 2022 Category: Drugs & Pharmacology Authors: Shu-Na Wang Zhi Wang Xi-Yuan Wang Xiu-Ping Zhang Tian-Ying Xu Chao-Yu Miao Source Type: research

A novel small-molecular CCR5 antagonist promotes neural repair after stroke
In this study we characterized the therapeutic potential of a novel CCR5 antagonist A14 in treating ischemic stroke mice. A14 was discovered in screening millions compounds in the Chemdiv library based on the molecular docking diagram of CCR5 and maraviroc. We found that A14 dose-dependently inhibited the CCR5 activity with an IC50 value of 4.29 μM. Pharmacodynamic studies showed that A14 treatment exerted protective effects against neuronal ischemic injury both in vitro and vivo. In a SH-SY5Y cell line overexpressing CCR5, A14 (0.1, 1 μM) significantly alleviated OGD/R-induced cell injury. We found that the expression o...
Source: Acta Pharmacologica Sinica - May 17, 2023 Category: Drugs & Pharmacology Authors: Qing-Lin Wu Li-Yuan Cui Wen-Yu Ma Sha-Sha Wang Zhao Zhang Zhong-Ping Feng Hong-Shuo Sun Shi-Feng Chu Wen-Bin He Nai-Hong Chen Source Type: research

Long-term administration of salvianolic acid A promotes endogenous neurogenesis in ischemic stroke rats through activating Wnt3a/GSK3 β/β-catenin signaling pathway
Acta Pharmacol Sin. 2022 Feb 25. doi: 10.1038/s41401-021-00844-9. Online ahead of print.ABSTRACTStroke is the major cause of death and disability worldwide. Most stroke patients who survive in the acute phase of ischemia display various extents of neurological deficits. In order to improve the prognosis of ischemic stroke, promoting endogenous neurogenesis has attracted great attention. Salvianolic acid A (SAA) has shown neuroprotective effects against ischemic diseases. In the present study, we investigated the neurogenesis effects of SAA in ischemic stroke rats, and explored the underlying mechanisms. An autologous throm...
Source: Acta Pharmacologica Sinica - February 26, 2022 Category: Drugs & Pharmacology Authors: Sen Zhang De-Wen Kong Guo-Dong Ma Cheng-di Liu Yu-Jiao Yang Shan Liu Nan Jiang Zi-Rong Pan Wen Zhang Ling-Lei Kong Guan-Hua Du Source Type: research

Deciphering the pharmacological mechanism of the Chinese formula Huanglian-Jie-Du decoction in the treatment of ischemic stroke using a systems biology-based strategy.
CONCLUSION: This study has developed for the first time a comprehensive systems approach integrating drug target prediction, network analysis and molecular docking simulation to reveal the relationships between the herbs contained in HLJDD and their putative targets and ischemic stroke-related pathways. PMID: 25937634 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - May 4, 2015 Category: Drugs & Pharmacology Authors: Zhang YQ, Wang SS, Zhu WL, Ma Y, Zhang FB, Liang RX, Xu HY, Yang HJ Tags: Acta Pharmacol Sin Source Type: research

Discovery and development of NA-1 for the treatment of acute ischemic stroke.
Abstract Stroke creates a complex interplay of multiple signaing pathways including excitotoxicity, ionic imbalance, inflammation, oxidative stress and apoptosis. There are very few treatments that have been shown to be beneficial in acute stroke. Recent findings have provided insights into the pathophysiology and mechanisms of ischemic stroke, complementing the traditional glutamate hypothesis: the molecular interaction between PSD95 and GluN2B has been identified as a culprit in stroke-mediated excitotoxicity, leading to the discovery of NA-1, a peptide that disrupts that interaction, as a potent neuroprotective...
Source: Acta Pharmacologica Sinica - March 22, 2018 Category: Drugs & Pharmacology Authors: Ballarin B, Tymianski M Tags: Acta Pharmacol Sin Source Type: research

Salvianolic acid A prevented cerebrovascular endothelial injury caused by acute ischemic stroke through inhibiting the Src signaling pathway.
In conclusion, our results suggest that SAA protects cerebrovascular endothelial cells against ischemia and OGD injury via suppressing Src signaling pathway. These findings show that pretreatment with SAA is a potential therapeutic strategy for the prevention of ischemic stroke. PMID: 33303991 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - December 10, 2020 Category: Drugs & Pharmacology Authors: Liu CD, Liu NN, Zhang S, Ma GD, Yang HG, Kong LL, Du GH Tags: Acta Pharmacol Sin Source Type: research

Angiogenesis after ischemic stroke
Acta Pharmacol Sin. 2023 Feb 24. doi: 10.1038/s41401-023-01061-2. Online ahead of print.ABSTRACTOwing to its high disability and mortality rates, stroke has been the second leading cause of death worldwide. Since the pathological mechanisms of stroke are not fully understood, there are few clinical treatment strategies available with an exception of tissue plasminogen activator (tPA), the only FDA-approved drug for the treatment of ischemic stroke. Angiogenesis is an important protective mechanism that promotes neural regeneration and functional recovery during the pathophysiological process of stroke. Thus, inducing angio...
Source: Acta Pharmacologica Sinica - February 24, 2023 Category: Drugs & Pharmacology Authors: Jie Fang Zhi Wang Chao-Yu Miao Source Type: research